Abstract
As a ubiquitous nuclear protein, high-mobility group box 1 (HMGB1) is constitutively expressed and can be actively secreted by macrophages/monocytes, as well as passively released from damaged cells following pathological injuries. Studies indicate that HMGB1 functions as a mediator of infection- and injury-elicited inflammatory diseases. Although intracellular HMGB1 functions as a regulator of tumorigenesis, epigenetic anticancer agents or therapeutic γ-ray irradiation could also cause active secretion or passive release of HMGB1, enabling serum HMGB1 to serve as a biomarker for the diagnosis and therapy of various cancers. Here we describe a semiquantitative immune blotting method to measure HMGB1 in human serum, in comparison with a commercially available HMGB1 enzyme-linked immunosorbent assay (ELISA) technique.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
